Clinical Trial

Impact of Covid-19 on Syphilis

Study acronym: SIPAND
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Sexually transmitted infections (STIs) represent a significant challenge to global public health. Although many of these infections are treatable, failure to diagnose and delayed treatment can lead to serious complications, including infertility, chronic inflammatory diseases, and an increased risk of HIV transmission. The COVID-19 pandemic has had a significant impact on healthcare management, the economy, and citizens' lifestyles. The first lockdown in the spring of 2020 affected the entire country, while in the following months, government measures were differentiated on a regional basis, with varying restrictions on activities and mobility. Physical distancing, the use of personal protective equipment, fear of contagion, and health restrictions contributed to a delay in STI diagnoses, resulting in an increase in transmission and severity of cases diagnosed after 2022.
Trial Details
NCT Number NCT07150871
Lead Sponsor Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Conditions Syphilis, COVID - 19, HIV (Human Immunodeficiency Virus), Retrospective Studies
Enrollment 240 participants
Start Date 2025-05-28
Primary Completion 2025-06-16 (estimated)
Study Completion 2026-05-28 (estimated)
Updated on ClinicalTrials.gov 2025-09-02